In the spring of 2014, a small Michigan-based biotech closed a $6.5 million deal to buy several cell therapies from the French drug giant Sanofi. They included a technology to treat weekend warriors with worn-out knees, and a new kind of skin graft for people with catastrophic burns.
Almost exactly five years later, the acquisitions look like a smart move.
